(Q35659915)

9 August 2017

8 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

13 December 2019

14 September 2020

Monoclonal antibodies in gynecological cancer: a critical point of view (English)

1 reference

9 August 2017

1 reference

27 September 2019

uterine cervix neoplasm

1 reference

14 September 2020

1 reference

14 September 2020

1 reference

14 September 2020

Chiara Napoletano

2

0 references

Ilary Ruscito

object named as

Ilary Ruscito

6

0 references

Maria Luisa Gasparri

object named as

Maria Luisa Gasparri

3

0 references

Filippo Bellati

object named as

Filippo Bellati

1

0 references

author name string

Valeria Visconti

4

1 reference

9 August 2017

Ilaria Grazia Zizzari

5

1 reference

9 August 2017

Jlenia Caccetta

7

1 reference

9 August 2017

Aurelia Rughetti

8

1 reference

9 August 2017

Pierluigi Benedetti-Panici

9

1 reference

9 August 2017

Marianna Nuti

10

1 reference

9 August 2017

publication date

26 December 2011

10 references

Clinical and Developmental Immunology

9 August 2017

13 March 2019

14 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

13 December 2019

29 May 2020

14 September 2020

10 references

9 August 2017

13 March 2019

14 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

13 December 2019

29 May 2020

14 September 2020

2011

1 reference

9 August 2017

page(s)

890758

1 reference

Creative Commons Attribution 3.0 Unported

9 August 2017

copyright license

9 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

27 September 2019

27 November 2019

13 December 2019

29 May 2020

on focus list of Wikimedia project

14 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Immune effects of trastuzumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Catumaxomab: clinical development and future directions

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Farletuzumab in epithelial ovarian carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Monoclonal antibodies in cancer therapy: 25 years of progress

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Human B-cell immune response to the polymorphic epithelial mucin.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic

27 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Immunotherapy of malignant ascites with trifunctional antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Vascular endothelial growth factor and prognosis of cervical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3253445

Cellular Adaptive Immune System Plays a Crucial Role in Trastuzumab Clinical Efficacy

23 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F890758

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer

21 January 2018

1 reference

12 December 2020

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

1 reference

12 December 2020

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer

1 reference

12 December 2020

The use of OKT3 to treat steroid-resistant renal allograft rejection in patients receiving cyclosporine

1 reference

12 December 2020

Bevacizumab therapy in patients with recurrent uterine neoplasms

1 reference

12 December 2020

Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13

1 reference

12 December 2020

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

12 December 2020

Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients

1 reference

12 December 2020

Is there a real standard for stage IVa cervical cancer?

1 reference

12 December 2020

Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy

1 reference

12 December 2020

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts

1 reference

12 December 2020

Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer

1 reference

12 December 2020

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

1 reference

12 December 2020

Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer

1 reference

12 December 2020

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

12 December 2020

Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model

1 reference

12 December 2020

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

1 reference

12 December 2020

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

1 reference

12 December 2020

1 reference

12 December 2020

Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis

1 reference

12 December 2020

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group

1 reference

12 December 2020

An update in neoadjuvant chemotherapy in cervical cancer

1 reference

12 December 2020

Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer

1 reference

12 December 2020

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1 reference

12 December 2020

Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma

1 reference

12 December 2020

Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma

1 reference

12 December 2020

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

1 reference

12 December 2020

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

1 reference

12 December 2020

Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo

1 reference

12 December 2020

Signal transduction by vascular endothelial growth factor receptors

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/890758

1 reference

9 August 2017

1 reference

9 August 2017

1 reference